Couldn't USA invest in the capability of producing those drugs locally?
this post was submitted on 23 Mar 2024
68 points (97.2% liked)
World News
32304 readers
422 users here now
News from around the world!
Rules:
-
Please only post links to actual news sources, no tabloid sites, etc
-
No NSFW content
-
No hate speech, bigotry, propaganda, etc
founded 5 years ago
MODERATORS
Something something capitalism I'm guessing
In theory yes, and in practice the US is planning on producing certain critical drugs locally, but most drugs will probably continue to be produced in India and China due to cost.
it makes perfect sense that one of the wealthiest countries, depends on poorer ones to produce their pharmaceuticals because of 'costs'. Seems legit.
And still charge insanely high prices. A side note: a local used to work at a now-closed child medicine manufacturing facility. His behavior became so volatile, everyone blamed it on that, but also he was in late adolescence under extreme conditions of despair.
The country isn't wealthy, but some individuals are and fantastically so. They won't manufacture this stuff at home because it'd mean pharma execs couldn't afford as many yachts
Well somebody ought to tell them that they should maybe put that +1000% margin they make on their drugs into that rather than lining their pockets.
God forbid the executives make a little less money - won't somebody think of those poor multi-millionaires! /s
Due to ~~cost~~ profit margins and shareholder returns.
Fixed that for you.
That would require an entire supply chain that also no longer exists in the US
This is a very valid question. They should be produced locally.
This is the best summary I could come up with:
India's lax regulatory oversight, analog practices where things should be digitized, and data integrity issues have far-reaching consequences that include hundreds of children dying from contaminated cough syrups across the world, and the potential to reshape geopolitical dynamics in the global drug trade.
"India can maintain its lead if it undertakes reforms to bring regulations closer to international standards, invests in state-of-the-art facilities and technology, and focuses on training," Yanzhong Huang, senior fellow in global health at American think tank Council on Foreign Relations (CFR), told Nikkei.
Taking advantage of cheaper infrastructure and inexpensive labor in countries like India and China, the U.S. relies on foreign manufacturers for more than half its active pharmaceutical ingredients (APIs) - the components responsible for the remedial effect in medicine - for its essential drugs.
The attitude is illustrative of a results-oriented culture where breaching guardrails stems from a place of getting things done amid resource constraints, Saswati Barat, an industrial psychologist and CEO of AIOU, a boutique behavioral consultancy, told Nikkei.
The concept of "manage," a colloquial Indian English term for quick-fix workarounds that often bend the rules to get things done, worries Ajaz Hussain, a former deputy director in the office of pharmaceutical science at the Center for Drug Evaluation and Research at the U.S. FDA.
Dinesh Thakur, a Ranbaxy whistleblower who exposed the drugmaker's violations, told Nikkei that senior leaders at Indian pharma companies are often reluctant to invest in digitalization, which would eliminate nearly all human intervention and minimize the possibility of fudged data.
The original article contains 3,669 words, the summary contains 254 words. Saved 93%. I'm a bot and I'm open source!